Nivolumab approved as first-line, single agent for advanced melanoma
Dermatologists’ management of melanoma varies
Immune-related events with checkpoint inhibitors are manageable
Immune-related patterns of response present challenges
Point/Counterpoint: What is the first-line treatment of choice for metastatic BRAF-mutant melanoma?
Mini X-Ray Device Treats Nonmelanoma Skin Cancers
Patient ResourcesMore ›
Decision Support in Medicine: Melanoma
VIDEO: Dual immunotherapy more powerful in melanoma, but where do we go from here?
VIDEO: Lymphadenectomies don’t boost survival in melanoma with SLN micrometastases
VIDEO: Updating the immune response to nonmelanoma skin cancer